/

COCP

Cocrystal Pharma, Inc.Closed

1.08+0.02 +1.89%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.05

Prev close

1.06

Day range

1.021.11

52-week range

0.76002.03

Volume

86.66K1.56×

Mkt cap

20.80M

P/E ttm

—

Fwd P/E

-2.27

EPS ttm

-0.7800

Div yield

0.00%

Earnings

—

From 52w high

−46.80%

Price Chart

Yahoo Finance · delayed

COCPOct 13, 2026O 1.05H 1.11L 1.02C 1.08+0.02 (+1.89%)Vol 86.70K

SMA 501.13
SMA 2001.11

1Y change +1.89% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

COCP Cocrystal Pharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.70%
1 month: −12.90%
3 months: +14.89%
6 months: −29.41%
Year to date: +10.20%
1 year: +1.89%

Valuation & ownership

Market cap: 20.80M
Enterprise value: 19.98M
P/E (ttm): —
Forward P/E: -2.27
PEG ratio: —
Price / book: 14.21
Price / sales (ttm): 63.04
EV / EBITDA: -1.99
EPS (ttm): -0.7800
EPS (forward): -0.4750
Beta (5y monthly): 1.48
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 19.26M
Float: 11.91M
Short % of float: 1.11%
Short ratio (days): 3.34
Held by insiders: 65.71%
Held by institutions: 5.77%
Avg volume (3m): 55.52K
50-day average: 1.13
200-day average: 1.11
52-week change: +1.89%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 43.5
vs 50-day SMA: −4.32%
vs 200-day SMA: −2.45%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.84%
Realised vol (20d, ann.): 47.5%
From 52-week high: −46.80%
From 52-week low: +42.11%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

8.00

+640.74% implied

Low 6.00Median 8.00High 10.00

Recommendation trend

Now2 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

DES

About Cocrystal Pharma, Inc.

Yahoo Finance profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.

Sector: Healthcare
Industry: Biotechnology
Employees: 10
Headquarters: Bothell, WA, United States
Website: cocrystalpharma.com
Officers: Prof. Roger D. Kornberg Ph.D. Co-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board

SEAS

Seasonality · COCP

2012–2026 · monthly returns

Strongest month Nov +21.34%Weakest month Sep −9.16%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.0	7.1	-3.8	41.6	-21.7	-6.3	-21.9	41.5	-0.9	-6.1			+10.2%
2025	-1.5	-13.1	-17.9	6.3	13.2	-12.9	16.1	-13.3	-16.7	-12.8	-2.8	-7.5	−51.5%
2024	-7.6	-10.1	-2.1	10.7	45.2	3.6	-18.0	-5.8	-2.2	0.6	16.9	-2.4	+17.4%
2023	44.6	-30.9	2.1	24.6	-12.9	10.6	11.3	12.8	-37.7	-8.6	11.1	-9.5	−11.8%
2022	-13.8	-3.6	1.9	-14.5	-14.9	2.5	-2.4	0.0	-27.5	-28.7	10.5	-28.8	−75.0%
2021	26.5	-8.7	-11.5	-15.1	-4.2	10.6	-7.2	0.9	-10.3	-15.2	1.1	-27.8	−52.2%
2020	26.0	111.1	-46.6	32.4	3.2	56.7	11.2	-37.3	-12.3	-10.8	160.2	-37.0	+172.0%
2019	-19.4	-0.7	-5.2	-6.6	-9.8	2.2	-3.0	0.4	-10.5	-63.9	-31.1	-2.0	−86.1%
2018	-29.8	-1.4	43.4	-64.4	8.0	59.8	13.7	-11.1	-32.4	-26.0	89.2	2.9	−40.0%
2017	0.0	-25.6	-6.9	0.0	-25.9	10.0	-9.1	25.0	8.0	-7.4	0.0	-20.0	−48.7%
2016	-31.5	-3.3	16.9	1.4	-7.1	-26.2	-6.3	-8.9	19.5	-2.0	-8.3	-11.4	−56.2%
2015	7.1	106.7	59.1	-20.9	2.6	-5.0	-20.2	-17.6	-14.7	6.3	7.4	21.9	+111.9%
2014	-10.9	1.8	-1.7	-28.1	-12.2	-11.1	-15.6	44.4	-7.7	52.8	-5.5	-19.2	−34.4%
2013	15.4	-28.0	-61.1	-52.4	10.0	-9.1	-4.0	0.0	22.9	23.7	0.0	-12.3	−80.3%
2012			-4.6	0.0	13.6	0.0	-56.3	0.0	-6.9	-8.0	50.0	44.4	−11.9%

INSD

Insider Activity · COCP

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 4, 2026	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.98 per share.	10K	$9.82K
Aug 2, 2026	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.94 per share.	75K	$70.59K
Feb 23, 2026	Frost Phillip Md Et AlDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 1.00 per share.	20K	$19.95K
Feb 5, 2026	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.95 per share.	50K	$47.28K
Dec 30, 2025	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.95 per share.	50K	$47.27K
Dec 29, 2025	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.97 per share.	20K	$19.31K
Dec 25, 2025	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.97 per share.	65K	$63.20K
Nov 25, 2025	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.99 - 1.00 per share.	4K	$3.98K
Nov 24, 2025	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.94 per share.	20K	$18.81K
Oct 27, 2025	Martin James J. CpaChief Executive Officer	Stock Award(Grant) at price 1.15 per share.	3.6K	$4.14K
Oct 27, 2025	Frost Phillip Md Et AlBeneficial Owner of more than 10% of a Class of Security	Stock Award(Grant) at price 1.15 per share.	359.7K	$413.67K
Oct 27, 2025	Hassan FredDirector	Stock Award(Grant) at price 1.15 per share.	359.7K	$413.67K
Oct 27, 2025	Pfenniger Richard C JrDirector	Stock Award(Grant) at price 0.00 per share.	20K	—

13F

Investors Holding COCP

latest 13F filings of 29 followed managers

Investors holding COCP
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$188.6K	0.00%	179.63K	+45%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

COCP

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

COCP

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cocrystal Pharma, Inc.

Seasonality · COCP

Insider Activity · COCP

Congress Trades · COCP

Investors Holding COCP

Investors Holding COCP

Congress Trades · COCP

Insider Activity · COCP

Seasonality · COCP

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cocrystal Pharma, Inc.

Financial Snapshot

Earnings & Dividends

News